MX2011010634A - Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. - Google Patents

Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa.

Info

Publication number
MX2011010634A
MX2011010634A MX2011010634A MX2011010634A MX2011010634A MX 2011010634 A MX2011010634 A MX 2011010634A MX 2011010634 A MX2011010634 A MX 2011010634A MX 2011010634 A MX2011010634 A MX 2011010634A MX 2011010634 A MX2011010634 A MX 2011010634A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
human monoclonal
lipopolysaccarides
lps
antibody specific
Prior art date
Application number
MX2011010634A
Other languages
English (en)
Spanish (es)
Inventor
Michael Rudolf
Holger Koch
Stefanie Fas
Original Assignee
Kenta Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech Ag filed Critical Kenta Biotech Ag
Publication of MX2011010634A publication Critical patent/MX2011010634A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011010634A 2009-04-09 2010-04-06 Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. MX2011010634A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005245 2009-04-09
PCT/EP2010/002158 WO2010115606A1 (en) 2009-04-09 2010-04-06 Human monoclonal antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
MX2011010634A true MX2011010634A (es) 2012-03-06

Family

ID=40934847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010634A MX2011010634A (es) 2009-04-09 2010-04-06 Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa.

Country Status (10)

Country Link
US (1) US20120114657A1 (enExample)
EP (1) EP2417157A1 (enExample)
JP (1) JP2012523221A (enExample)
KR (1) KR20120016086A (enExample)
CN (1) CN102639562A (enExample)
BR (1) BRPI1013427A2 (enExample)
CA (1) CA2758081A1 (enExample)
IL (1) IL215549A0 (enExample)
MX (1) MX2011010634A (enExample)
WO (1) WO2010115606A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130004499A1 (en) * 2010-02-18 2013-01-03 Symphogen A/S Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa
JP6058645B2 (ja) * 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
PT2776065T (pt) 2011-11-07 2020-09-25 Medimmune Ltd Terapias de combinação que usam moléculas de ligação de psl e pcrv anti-pseudomonas
AU2016353073A1 (en) 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US11969476B2 (en) 2020-04-03 2024-04-30 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE60331292D1 (de) * 2003-05-14 2010-04-01 Kenta Biotech Ag Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa
EP1690875A1 (en) * 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype

Also Published As

Publication number Publication date
IL215549A0 (en) 2011-12-29
KR20120016086A (ko) 2012-02-22
EP2417157A1 (en) 2012-02-15
US20120114657A1 (en) 2012-05-10
JP2012523221A (ja) 2012-10-04
CA2758081A1 (en) 2010-10-14
WO2010115606A1 (en) 2010-10-14
CN102639562A (zh) 2012-08-15
BRPI1013427A2 (pt) 2016-04-05

Similar Documents

Publication Publication Date Title
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
UA101487C2 (en) Humanized b-ly1 antibody formulation
IN2012DN00797A (enExample)
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MY160736A (en) Bivalent, bispecific antibodies
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
WO2009083009A3 (en) Monoclonal antibodies against cd32b
UA109658C2 (xx) Антитіло проти cgrp
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010066803A3 (en) Human antibodies against human tissue factor
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
MX2010003574A (es) Anticuerpos il-23.
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2011010634A (es) Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa.
EP3492101A3 (en) Agents for influenza neutralization
IL184774A0 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
MX347978B (es) Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal